Vericel Announces Appointment of Joe Mara as Chief Financial Officer
January 25 2021 - 7:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, announced the
appointment of Joe Mara as Chief Financial Officer of the Company,
effective today.
Mr. Mara joins Vericel with over 20 years of financial,
strategic and operational experience, including more than 14 years
of experience in the biotech industry. Most recently, Mr. Mara
served as Vice President, Finance and Head of Investor Relations at
Biogen Inc. During his tenure at Biogen, Mr. Mara held several
finance leadership roles, including Vice President, Global
Financial Planning and Analysis and Strategic Corporate Finance and
Vice President, U.S. Finance and Operations. Prior to joining
Biogen, Mr. Mara held finance and strategy roles in the financial
services and technology industries, including at Thomson Reuters
Corporation and Fidelity Investments. Mr. Mara earned a B.A. degree
in Economics and International Studies from Northwestern University
and an M.B.A. from the Sloan School of Management at M.I.T.
“Joe is a proven finance and business leader with a track record
of success in operational and strategic finance roles across U.S.
and global organizations,” said Nick Colangelo, President and Chief
Executive Officer of Vericel. “I am very pleased that Joe is
joining the Vericel executive team at a time when his extensive
experience will help drive continued strong growth and financial
results for the Company in the years ahead.”
“I am very excited to join Vericel given its leadership position
in cell therapy and the sports medicine and severe burn care
markets, its innovative product portfolio, and the Company’s
significant growth potential,” said Mr. Mara. “I look forward to
working with the Vericel team to continue to provide important
products to patients, execute on the Company’s long-term growth
strategy, and drive continued value for our shareholders.”
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company’s website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2021 Vericel
Corporation. All rights reserved.
Forward Looking StatementsThis press release
contains forward-looking statements. Forward-looking statements are
subject to risks and uncertainties such as those described
in Vericel’s periodic reports on file with the Securities
and Exchange Commission. Actual results may differ materially from
anticipated results.
Investor Contacts:Chad RubinSolebury
Troutcrubin@troutgroup.com+1 646-378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024